Your browser doesn't support javascript.
loading
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.
Mendoza-Valderrey, Alberto; Alvarez, Maite; De Maria, Andrea; Margolin, Kim; Melero, Ignacio; Ascierto, Maria Libera.
Afiliação
  • Mendoza-Valderrey A; Rosalie and Harold Rae Brown Cancer Immunotherapy Research Program, Borstein Family Melanoma Program, Translational Immunology Department, Saint John's Cancer Institute, Santa Monica, CA 90404, USA.
  • Alvarez M; Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, 31008 Pamplona, Spain.
  • De Maria A; Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.
  • Margolin K; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
  • Melero I; Department of Health Sciences, University of Genoa, 16126 Genova, Italy.
  • Ascierto ML; IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Cells ; 11(19)2022 10 06.
Article em En | MEDLINE | ID: mdl-36231109
In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Cells Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça